In vivo RNAi delivery

By Press release
Monday, 16 February, 2009


Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.

Invitrogen

www.invitrogen.com/invivornai

Related Articles

Novel drug candidates found for nerve pain and ischemic disease

The discovery paves the way for potential new treatments for health conditions linked to tissue...

Real-time sequencing helps combat golden staph infections

Tracking bacterial changes during serious Staphylococcus aureus (golden staph) infection...

Single-cell sequencing capability boosted in South Australia

The South Australian Genomics Centre has become the first certified service provider in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd